A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)

Clinical trial NCT07005128 · RECRUITING

Trial details

NCT number: NCT07005128
Sponsor: Amgen
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Small-cell Lung Cancer Extensive Stage Small-cell Lung Cancer

Start date: 2025-08-18
Primary completion: 2029-01-04
Enrollment: 330

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.